<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991327</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-106</org_study_id>
    <nct_id>NCT01991327</nct_id>
  </id_info>
  <brief_title>Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males</brief_title>
  <official_title>AN OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE DRUG-DRUG INTERACTIONS OF ANDROXAL WITH CYTOCHROME P450 ISOENZYMES IN HEALTHY MALE SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the drug-drug interactions of Androxal with&#xD;
      cytochrome P450 isoenzymes, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in healthy&#xD;
      male subjects administered 25 mg Androxal once daily for 3 days. Secondly, the safety and&#xD;
      tolerability of Androxal will be determined in healthy male subjects administered Androxal 25&#xD;
      mg daily for 3 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug-Drug Interaction</measure>
    <time_frame>3 days</time_frame>
    <description>The primary objective of this study is to assess the drug-drug interactions of Androxal with cytochrome P450 isoenzymes, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in healthy male subjects administered 25 mg Androxal once daily for 3 days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Drug-drug Interaction</condition>
  <arm_group>
    <arm_group_label>Androxal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androxal 25 mg capsules once a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Androxal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal</intervention_name>
    <arm_group_label>Androxal</arm_group_label>
    <other_name>enclomiphene citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Androxal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Speak, read, and understand English or Spanish and is willing and able to provide&#xD;
             written informed consent on an institutional review board (IRB)-approved form prior to&#xD;
             the initiation of any study procedures;&#xD;
&#xD;
          -  Healthy male, between the ages of 18 and 60 years; body mass index (BMI) 19.0-29.9.&#xD;
&#xD;
          -  All laboratory tests either within the normal range or assessed as not clinically&#xD;
             significant by the Principal Investigator. Any clinically significant deviations&#xD;
             outside of the normal range in the opinion of the Principal Investigator will require&#xD;
             sponsor approval. A negative hepatitis B surface antigen, hepatitis C antibody or HIV&#xD;
             antibody test result within the previous 3 months may be used instead of obtaining a&#xD;
             screening laboratory sample for these laboratory tests;&#xD;
&#xD;
          -  Ability to complete the study in accordance with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Clomid;&#xD;
&#xD;
          -  A clinically significant laboratory abnormality or other clinical findings indicative&#xD;
             of a clinically significant exclusionary disease including hepatic insufficiency,&#xD;
             renal insufficiency, unstable coronary artery disease, malignancy other than basal&#xD;
             cell carcinoma or squamous cell carcinoma of the skin or stroke;&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis surface B antigen (HBsAg) and&#xD;
             hepatitis C antibody;&#xD;
&#xD;
          -  A positive test result for HIV;&#xD;
&#xD;
          -  Positive results from a urine screen for substances of abuse;&#xD;
&#xD;
          -  A recent history of alcoholism (&lt; 2 years) or of moderate alcohol use (greater than an&#xD;
             average of 3 drinks per day or a total of 21 drinks per week) or use of alcohol within&#xD;
             24 hours prior to receiving the first dose of study medication;&#xD;
&#xD;
          -  Use of any recreational drugs within the past year or a previous history of drug&#xD;
             abuse;&#xD;
&#xD;
          -  Use of an investigational drug or product, or participation in a drug research study&#xD;
             within 30 days prior to receiving study medication;&#xD;
&#xD;
          -  A clinically significant electrocardiogram (ECG) abnormality;&#xD;
&#xD;
          -  A history of difficulty with phlebotomy;&#xD;
&#xD;
          -  Donation of blood (1 pint or more) within 30 days, or plasma within 7 days prior to&#xD;
             receiving study medication;&#xD;
&#xD;
          -  Use of any prescription drug therapy within 14 days prior to receiving study&#xD;
             medication;&#xD;
&#xD;
          -  Use of any over-the-counter (OTC) drugs for therapeutic purposes within 48 hours prior&#xD;
             to receiving study medication; Use of dietary or herbal supplements 14 days prior to&#xD;
             study or megavitamin supplements within 48 hours prior to receiving study medication;&#xD;
&#xD;
          -  Consumption of any caffeine containing foods or beverages within 48 hours prior to&#xD;
             receiving study medication;&#xD;
&#xD;
          -  Consumption of any grapefruit or grapefruit-containing juices, vegetables from the&#xD;
             mustard green family, and charbroiled meat within 72 hours prior to receiving study&#xD;
             medication;&#xD;
&#xD;
          -  Current smoker or user of any tobacco products that has smoked in last 30 or 60 days;&#xD;
&#xD;
          -  Any condition which, in the opinion of the Principal Investigator, could interfere&#xD;
             with the subject's ability to provide informed consent, comply with study&#xD;
             instructions, possibly confound interpretation of study results, or endanger the&#xD;
             subject if he took part in the study;&#xD;
&#xD;
          -  Classified as a cytochrome P450 isoenzyme 2D6 (CYP2D6) &quot;poor metabolizer&quot; as&#xD;
             determined by genotyping at the screening visit&#xD;
&#xD;
          -  Use of a monoamine oxidase (MAO) Inhibitor in the previous 28 days prior to dose.&#xD;
&#xD;
          -  Concurrent use of cimetidine, levodopa, amantadine, other antipsychotics or&#xD;
             antidepressants.&#xD;
&#xD;
          -  Type I or Type II diabetes&#xD;
&#xD;
          -  Clinical evidence of cirrhosis or biopsy proven cirrhosis of any etiology&#xD;
&#xD;
          -  Screening liver function tests (ALT, AST, Bil, Alk. Phos) greater than upper limit of&#xD;
             normal&#xD;
&#xD;
          -  History of hypertension with BP &gt; 150/95 mmHg seated at screening&#xD;
&#xD;
          -  History of chronic pancreatitis or cholelithiasis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Sponsor corporate website</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

